Russell Alan J. - 07 Mar 2025 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)

Signature
/s/ John R. Moore Attorney-in-Fact for Alan J Russell
Issuer symbol
EWTX
Transactions as of
07 Mar 2025
Net transactions value
-$5,968
Form type
4
Filing time
11 Mar 2025, 16:33:15 UTC
Previous filing
07 Feb 2025
Next filing
07 May 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EWTX Common Stock Options Exercise $36 +200 +1.3% $0.1800 15,063 07 Mar 2025 Direct
transaction EWTX Common Stock Sale $6,004 -200 -1.3% $30.02 14,863 07 Mar 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EWTX Stock Option (Right to Buy) Options Exercise $0 -200 -0.01% $0.000000 1,456,580 07 Mar 2025 Common Stock 200 $0.1800 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 30, 2024.
F2 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.04, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 This Option was fully vested on June 27, 2021.